Connect with us

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website. .

Top Stories

Exclusive-Big hedge funds call on doctors, scientists for an edge on pharma, sources say
Gloved hand holds pill with tweezers in laboratory.

Published : , on

By Nell Mackenzie

LONDON (Reuters) – Some of the world’s largest hedge funds are hiring doctors, scientists and analysts to give them expert insight into the prospects for pharmaceutical stocks after big share swings in the sector, eight sources told Reuters.

This year has seen sharp stock moves as companies report financial results and update investors on early and mid-stage drug studies.

Abbvie shares opened 11% lower on Nov. 11 after the company announced its mid-stage schizophrenia drug trials had failed. The same day, rival Bristol Myers Squibb shares rose almost 13% in pre-market trade.

Shares of Novo Nordisk, one of Europe’s biggest listed companies, surged more than 7% in one day following November third-quarter guidance including better-than-expected sales of its popular Wegovy weight-loss drug.

Hedge funds, known for splashing out to gain a technological or research-based edge on market trends, are paying attention. Some of the biggest multi-strategy hedge funds are now looking to hire doctors and medical scientists globally and in Europe, said two people with knowledge of the firms’ mandate for recruitment that has kicked off in the past six months.

These include Balyasny, D.E. Shaw, Point72, Schonfeld, Qube and Squarepoint, together overseeing more than $200 billion in assets, the sources said. All the funds declined to comment. Hedge funds employ such experts in research departments to provide insights on company growth prospects, including any early-stage drug trials ultimately gaining regulatory approval, said another recruiter and two investors.

All spoke on condition of anonymity because the details are private.

Multi-strategy hedge funds, which are among the largest in the industry, pursue diverse investment approaches under the same roof.

Some use independent teams called “pods”, within which researchers work as part of a team led by a portfolio manager. Other multi-strategy funds have more collaborative structures, employing analysts with scientific and medical backgrounds as resident experts.

MEDICAL ASSISTANCE

In the past, hedge funds have hired scientists with specialist knowledge such as geology or engineering to inform commodities trading, said two sources with knowledge of how the funds work.

Weather engineers and meteorologists are regularly hired by the biggest to monitor fluctuations in the weather to inform trading in the power market.

Research and development in the pharmaceutical industry is expected to expand as borrowing costs in the wider economy begin to drop.

“The prospect of falling rates has seen multi-strategy hedge funds ramp up their hiring in healthcare,” Freddie Stacy, co-founder of recruitment firm Sheridan Executive, said.

“It has in the past been a massive space in the States, but for the first time we’re seeing a fresh interest in European healthcare personnel.”

Hedge fund hiring of healthcare professionals and scientists particularly ramped up in the U.S. after the COVID-19 vaccine approval process, he said.

The trend had spread to Europe in the last six months and intensified alongside advancements in the ability of artificial intelligence to make connections and discoveries in pharmaceuticals, Stacy added.

He could not go into further detail on the number of medical professionals and scientists he had placed at hedge funds, as the placements are private. European companies have seen near record-high volatility on earnings days this year, up almost a fifth from eight years ago, a recent Reuters analysis showed. Experts singled out multi-strategy hedge funds as one of the drivers of the phenomenon.

The funds have posted an 8.5% return in 2024 to the end of October, beating the wider industry which has returned 7.6% in the same period, according to hedge fund research firm PivotalPath. Culturally, doctors might match with hedge funds, said Stacy. Ex-doctors are attractive because if you can deal with the kind of extreme trauma seen daily by the medical profession, you can certainly handle draw-downs on a trading floor,” he said.

“Hedge funds want people with grit and determination  – and even a little humility.”

 

(Reporting by Nell Mackenzie; Editing by Dhara Ranasinghe, Elisa Martinuzzi and Jan Harvey)

 

Uma Rajagopal has been managing the posting of content for multiple platforms since 2021, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune. Her role ensures that content is published accurately and efficiently across these diverse publications.

Global Banking & Finance Review

 

Why waste money on news and opinions when you can access them for free?

Take advantage of our newsletter subscription and stay informed on the go!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Post